Allied Minds PLC ABLS II Completes Drug Feasibility Programme (1945Z)
May 25 2016 - 2:00AM
UK Regulatory
TIDMALM
RNS Number : 1945Z
Allied Minds PLC
25 May 2016
25 MAY 2016
Allied Minds plc
Allied Minds announces successful completion of ABLS II drug
candidate feasibility programme and approval of up to $15 million
to fund further drug development
-- Allied-Bristol Life Sciences, LLC (ABLS) has successfully
completed the drug candidate feasibility programme at ABLS II, LLC
(ABLS II)
-- ABLS has approved up to $15 million to fund further
development of the lead optimisation programme
-- ABLS II is seeking to develop novel small molecule
therapeutics for the treatment of fibrotic and autoimmune
diseases
-- It is intended that ABLS Capital, LLC (ABLS Capital) will
fund 80% of the next phase of development, with Bristol-Myers
Squibb Company (BMS) funding the remaining 20%
Boston, MA (25 May 2016) - Allied Minds (LSE: ALM), a
diversified holding company focused on venture creation within the
life science and technology sectors, today announces that
Allied-Bristol Life Sciences, LLC (ABLS), its partnership with
Bristol-Myers Squibb Company (BMS), has successfully completed the
drug candidate feasibility programme at ABLS II, LLC (ABLS II), and
has approved up to $15 million to fund further development of the
lead optimisation programme. It is intended that ABLS Capital, LLC,
which includes Allied Minds, Woodford Investment Management and
Invesco Asset Management among its investors, will fund 80% of this
phase of development, with BMS funding the remaining 20%.
ABLS is a drug discovery company focused on identifying and
developing biopharmaceutical innovations from leading U.S.
universities and research institutions that it believes have
significant therapeutic and commercial potential. ABLS focuses on
early-stage opportunities in key therapeutic areas including
fibrosis, cardiovascular, oncology, immunology and genetically
defined diseases. ABLS has launched three subsidiaries; ABLS I,
ABLS II and i<BETA>eCa Therapeutics to license and initiate
development work on proprietary assets from Yale University,
Harvard University and NYU School of Medicine, respectively.
ABLS II is seeking to develop novel small molecule therapeutics
for the treatment of fibrotic and autoimmune diseases, and is based
on research and intellectual property developed in the Harvard
University laboratory of Professor Malcolm Whitman.
Chris Silva, CEO of Allied Minds, said: "This is an exciting
milestone for our ABLS partnership with BMS. Of the three
subsidiaries launched by ABLS in the last 12 months to undertake
development work on proprietary assets from leading research
institutions, ABLS II is the first to successfully complete the
drug candidate feasibility programme. It is therefore the first to
obtain joint approval and funding from Allied Minds and BMS to
continue the lead optimisation programme and the identification of
pre-clinical drug candidates for potential sale to BMS."
ABLS Capital was formed last month with the sole purpose of
investing in ABLS subsidiaries as their assets enter the
Optimisation Phase. ABLS II represents the first example of this
novel, de-risked approach to drug development.
- Ends-
For more information, please contact:
Allied Minds plc
------------------------------ -----------------------------
Chris Silva, Chief Executive
Officer +1 617 419 1800
------------------------------ -----------------------------
www.alliedminds.com
------------------------------ -----------------------------
Citigate Dewe Rogerson
------------------------------ -----------------------------
Patrick Donovan/Rob Newman +44 20 7638 9571
------------------------------ -----------------------------
alliedminds@citigatedr.co.uk
------------------------------ -----------------------------
Notes to Editors
About Allied Minds
Allied Minds (LSE: ALM) is a diversified holding company focused
on venture creation within the life science and technology sectors.
With unparalleled access to hundreds of university and federal labs
across the U.S., Allied Minds forms, funds, and operates a
portfolio of companies to generate long-term value for its
investors and stakeholders. Based in Boston, with offices in Los
Angeles and New York, Allied Minds supports its businesses with
capital, central management, and shared services. For more
information, please visit www.alliedminds.com.
Allied Minds Forward-Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risk and uncertainties described in the risk factors
included in the company's regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law, regulatory requirement, the Listing Rules and the
Disclosure and Transparency Rules, neither the company nor any
other party intends to update or revise these forward-looking
statements, whether as a result of new information, future events
or otherwise.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBIGDUGDDBGLS
(END) Dow Jones Newswires
May 25, 2016 02:00 ET (06:00 GMT)
Allied Minds (LSE:ALM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allied Minds (LSE:ALM)
Historical Stock Chart
From Apr 2023 to Apr 2024